
It's Movember, and so I think that it is only fitting that I dedicate a post to prostate cancer. As it so happens, the latest update on the SELenium and vitamin E Cancer Prevention trial (SELECT) was recently published [1]. An excellent summary of this study by it's primary funder (provided $129,687,000 - ouch), the National Cancer Institute, is available online here.
Before reviewing the study, lets hop in the DeLorean and head back to 2001. It was a much simpler time - no Facebook, HP and LOTR were just hitting the big screen, Jean Chretien is PM, and Dan Cloutier is the Canuck netminder. The incidence (# of new cases) of prostate cancer has increased dramatically in the last decade, which is mainly attributable to increases in screening including the widespread availability of the prostate-specific antigen (PSA) test. Interesting side note, the routine screening for prostate cancer using PSA is highly debated today amongst expert organizations (for: American Urological Association / American Cancer Society; against: U.S. Prevention Services Task Force) [2]. Back in 2001, there is a growing body of evidence that dietary antioxidants may be able to prevent certain cancers. Two clinical trails, neither designed to measure prostate cancer, are published indicating a large benefit of supplementation with vitamin E [3], and selenium [4] for the prevention of prostate cancer:
[3] The Alpha-Tocopherol, Beta-Carotene (ATBC) trial was designed to evaluate the effect of supplementing antioxidants, vitamin E (aka alpha-tocopherol) and beta-carotene (precursor for vitamin A), on lung cancer prevention in male Finnish smokers 50-69 years old. Interestingly, this study [5], along with the CARET study [6], are often cited as warnings against the use of antioxidants supplements. However, further analysis of the ATBC study found a 36% reduction in prostate cancer incidence in the group receiving vitamin E.
[4] The Nutrition Prevention of Cancer (NPC) study is a secondary prevention study that was designed to evaluate the effect of selenium supplementation on preventing the recurrence of basal or squamous cell carcinoma (skin cancer) among patients referred to dermatology centers in the U.S. with non-malignant skin cancer. Although there was no benefit for preventing skin cancer recurrence, the group receiving selenium had 0.35 times the risk (2.85-fold decrease in risk) of developing prostate cancer.
Overall, the data at the time suggested (quite convincingly) that both vitamin E and selenium supplementation might be able to reduce the occurrence of prostate cancer. I'd like to take a moment to acknowledge that my previous sentiments regarding the paramount importance of coming up with a catchy acronym for research studies are well supported in this literature - SELECT, ATBC, CARET, NPC.
Flashback to the present, the SELECT study. It was a 2x2 clinical trial of selenium (200 mcg/d) and vitamin E (400 IU/d), meaning that participants were randomly allocated to one of four treatment groups:
1 - selenium and placebo
2 - vitamin E and placebo
3 - selenium and vitamin E
4 - placebo and placebo
This was relatively large trial, including 35,533 older men from US, Canada and Puerto Rico with 2,279 incident (new) cases of prostate cancer. In 2008, a preliminary analysis of the data indicated that it was very unlikely that a significant beneficial effect of supplementation would be detected, and that there might even be an increased risk of prostate cancer in the group receiving vitamin E. Consequently, subjects were instructed to stop taking their supplements, but were invited to continue to participate in monitoring. Last month, they published an updated analysis that including the time since stopping supplementation, and noted the following:

This graph depicts just the raw data - how many men were diagnosed with prostate cancer (total) in each of the groups. By year nine, the number of men with prostate cancer was lowest in the placebo group (n = 529) and highest in the vitamin E group (n = 620). After the initial release of data in 2008 (approximately year 6 in the above graph), the number of men still participating in the study decreased (year 6 = 19,218; year 7 = 12,129; year 8 = 5,483; year 9 = 186), which introduced bias into the results. This is best demonstrated by looking at the annual risk of developing prostate cancer by year:




As can be seen, for most years, close to 1% of the men in the study developed prostate cancer with the exception of year 9, where apparently there was a prostate cancer outbreak (not really). If we remove the 9th year from this table, it is possible to look at the annual risk by groups more closely:

As you can see, the risk of prostate cancer by group was similar each year with a slight, but statistically significant greater risk in the vitamin E group when adding all the years up. Overall, men receiving vitamin E were found to be 1.17 times more likely to be diagnosed with new cases of prostate cancer. This increased risk may sound like a lot, but it translates into an additional 1.6 new cases of prostate cancer annually per 1,000 men taking 400IU/day of vitamin E.
So why the disappointing results - the easiest and perhaps most accurate response is we don't know. The study populations of the previous clinical trials that showed considerable promise were smokers and individuals with skin cancer, both conditions that may be related to oxidative stress that benefits from antioxidants. Another possibility is that the previous research findings were false. In research, the convention is to allow for a 5% probability that the results could have happened by chance alone - when data mining a study like the ATBC trial, looking at hundreds of different outcomes that weren't part of the initial research question, it is reasonable to assume that statistically significant relationships may appear by chance or bias alone. For example, one of the initial findings from the SELECT study in the 2008 analysis was that participants in the selenium group trended towards increased risk of developing diabetes. This will undoubtedly be cited as a reason for future research into the possibility that selenium supplementation may increase the risk of diabetes in older men.
Perhaps the most compelling explanations for why vitamin E appeared to increase the risk of developing prostate cancer was the dose used. The dose was 400 IU/day, which greatly exceeds the amount of vitamin E that is estimated to meet the needs of 98% of healthy adult males (22.4 IU/day). The 'more is better' approach to nutrients is pervasive in our society, yet these mega-doses beyond what is normally found in food are not without risks. Below is a classic diagram relating to essential nutrients that most (presumably all) dietitians in Canada are quite familiar with:

This U-shaped curve describes the relationship between intake of an essential nutrient and health. I use the term "essential nutrient" quite deliberately because only essential nutrients results in adverse events at inadequate intakes. It may surprise some to learn that many of the nutrients that are advertised on food labels (ie. plant sterols for cholesterol lowering) are not required in the diet for health. These nutrients are more akin to drugs, and are the driving force behind the ever-growing nutraceutical (aka pharmaconutrition) and functional food industries.
The SELECT study seems destined to serve as another cautionary tale for supplement users. Attempts to identify and encapsulate the roughly 5,000+ bioactive phytonutrients (nutrients found in plants), and determine who will benefit from supplementation and at what dose will surely keep nutritionists such as myself occupied and employed for a long time to come. Until we know more, I would recommend that healthy adults aim to get their antioxidants from food with the appreciation that more isn't always better.
[1] Klein et al. Vitamin E and the risk of prostate cancer: The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2011; 306(14): 1549-56.
[2] Hoffman RM. Screening for prostate cancer. NEJM 2011; 365: 2013-9.
[3] Heinonen et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. JNCI 1998; 90: 440-6.
[4] Clark et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial. JAMA 1996; 276(24): 1957-63.
[5] Heinonen et al. The effect of vitamin E and beta-carotene on the incidence of lung cnacer and other cancers in male smokers. NEJM 1994; 330: 1029-35.
[6] Omenn et al. Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. NEJM 1996; 334: 1150-5.